TNF (TNF)

tumor necrosis factor /6p21.3
Previous Symbols: TNFA
Synomyms: TNFSF2,DIF,TNF-alpha
Entrez Gene: 7124
Uniprot: P01375
HUGO Accession: HGNC:11892

Other networks that feature this node:
Naturopathic Agents [click for references]
  • Kaempferol
  • Gossypol
  • Vidanga (Embelia ribes)
  • Astragalus (Astragalus membranaceus)
  • Echinacea (Echinacea spp.)
  • Milk thistle (Silybum marianum)
  • Honokiol
  • Peony root
  • Boswellia gum substance
  • Eupatorium adenophorum
  • Andrographis paniculata
  • Andrographolide
  • Betaine
  • Silibinin
  • Vitamin E restricted diet
  • Anthocyanins
  • Chokeberry
  • Embelin
  • Bromelain
  • Paeonia lactiflora
  • Boswellia serrata





  • OMIM (Online Mendellian Inheritance in Man)

    OMIM: 191160
    DESCRIPTION

    Tumor necrosis factor (TNF) is a multifunctional proinflammatory cytokine secreted predominantly by monocytes/macrophages that has effects on lipid metabolism, coagulation, insulin resistance, and endothelial function. TNF was originally identified in mouse serum after injection with Mycobacterium bovis strain bacillus Calmette-Guerin (BCG) and endotoxin. Serum from such animals was cytotoxic or cytostatic to a number of mouse and human transformed cell lines and produced hemorrhagic necrosis and in some instances complete regression of certain transplanted tumors in mice (Shirai et al., 1985; Pennica et al., 1984).

    CLONING

    Pennica et al. (1984) identified a monocyte-like human cell line that provided a source of TNF and its messenger RNA. cDNA clones were isolated, sequenced, and translated in E. coli. TNF and LTA (153440), or TNFB, have similar biologic activities and share 30% amino acid homology.

    Wang et al. (1985) and Shirai et al. (1985) independently cloned cDNA sequences corresponding to the human TNF gene. The deduced 233-amino acid protein has a long leader sequence of 76 residues. The gene was expressed in E. coli, and the protein product produced necrosis of murine tumors in vivo.

    TNF is synthesized as a 26-kD membrane-bound protein (pro-TNF) that is cleaved by processing enzymes (see, e.g., ADAM17; 603639 and Black et al., 1997) to release a soluble 17-kD TNF molecule The soluble molecule can then bind to its main receptors TNFR1 (191190) and TNFR2 (191191) (Skoog et al., 1999).

    GENE FUNCTION

    Aggarwal et al. (1985) presented evidence that TNF-alpha and TNF-beta share a common receptor on tumor cells and that the receptors are upregulated by gamma-interferon. Various interferons have been known to be synergistic with TNF in antitumor effects in vitro. Brenner et al. (1989) demonstrated that TNFA stimulates prolonged activation of the oncogene JUN expression; the JUN gene (165160) encodes transcription factor AP-1, which stimulates collagenase gene transcription. Thus, activation of JUN and collagenase gene expression may be one mechanism for mediating some of the biologic effects of TNFA.

    Obeid et al. (1993) found that the intracellular concentration of ceramide increased by 45% at 10 minutes after the addition of TNF-alpha to cells in vivo. Treatment of cells with ceramide directly induced DNA fragmentation, an early marker of apoptosis. The authors concluded that TNF-alpha resulted in sphingomyelin hydrolysis, production of ceramide, and ceramide-mediated apoptosis.

    Franchimont et al. (1999) examined the ability of TNFA and IL10 (124092) to regulate differentially the sensitivity of human monocytes/macrophages to glucocorticoids. Dexamethasone had different effects on LPS-induced TNFA and IL10 secretion; whereas it suppressed TNFA in a dose-dependent fashion, its effect on IL10 secretion was biphasic, producing stimulation at lower doses and inhibition at higher doses. The concentration of LPS employed influenced the effect of dexamethasone on IL10 secretion (P less than 0.001). Pretreatment with TNFA diminished, and with IL10 improved, the ability of dexamethasone to suppress IL6 (147620) secretion in whole-blood cell cultures (P less than 0.01 for both) and to enhance IL1 receptor antagonist (IL1RN; 147679) secretion by U937 cells (P less than 0.05 for both). TNFA decreased (P less than 0.001), while IL10 increased (P less than 0.001), the concentration of dexamethasone binding sites in these cells, with no discernible effect on their binding affinity. The authors concluded that glucocorticoids differentially modulate TNFA and IL10 secretion by human monocytes in an LPS dose-dependent fashion, and that the sensitivity of these cells to glucocorticoids is altered by TNFA or IL10 pretreatment; TNFA blocks their effects, whereas IL10 acts synergistically with glucocorticoids.

    Garcia-Ruiz et al. (2003) studied the contribution of ASM in TNF-alpha-mediated hepatocellular apoptosis. They showed that selective mGSH (mitochondrial glutathione) depletion sensitized hepatocytes to TNF-alpha-mediated hepatocellular apoptosis by facilitating the onset of mitochondrial permeability transition. Inactivation of endogenous hepatocellular ASM activity protected hepatocytes from TNF-alpha-induced cell death. Similarly, ASM -/- mice were resistant in vivo to endogenous and exogenous TNF-alpha-induced liver damage. Targeting of ganglioside GD3 (601123) to mitochondria occurred in ASM +/+ but not in ASM -/- hepatocytes. Treatment of ASM -/- hepatocytes with exogenous ASM induced the colocalization of GD3 and mitochondria. Garcia-Ruiz et al. (2003) concluded that ASM contributes to TNF-alpha-induced hepatocellular apoptosis by promoting the targeting of mitochondria by glycosphingolipids.

    Beattie et al. (2002) demonstrated that TNF-alpha, produced by glia, enhances synaptic efficacy by increasing surface expression of AMPA receptors. Preventing the actions of endogenous TNF-alpha has the opposite effects. Thus, Beattie et al. (2002) concluded that the continual presence of TNF-alpha is required for preservation of synaptic strength at excitatory synapses. Through its effects on AMPA receptor trafficking, TNF-alpha may play roles in synaptic plasticity and modulating responses to neural injury.

    Ruuls and Sedgwick (1999) reviewed the problem of unlinking TNF biology from that of the MHC. Dysregulation and, in particular, overproduction of TNF have been implicated in a variety of human diseases, including sepsis, cerebral malaria (611162), and autoimmune diseases such as multiple sclerosis (MS; 126200), rheumatoid arthritis, systemic lupus erythematosus (152700), and Crohn disease (see 266600), as well as cancer. Susceptibility to many of these diseases is thought to have a genetic basis, and the TNF gene is considered a candidate predisposing gene. However, unraveling the importance of genetic variation in the TNF gene to disease susceptibility or severity is complicated by its location within the MHC, a highly polymorphic region that encodes numerous genes involved in immunologic responses. Ruuls and Sedgwick (1999) reviewed studies that had analyzed the contribution of TNF and related genes to susceptibility to human disease, and they discussed how the presence of the TNF gene within the MHC may potentially complicate the interpretation of studies in animal models in which the TNF gene is experimentally manipulated.

    Progressive oligodendrocyte loss is part of the pathogenesis of MS. Oligodendrocytes are vulnerable to a variety of mediators of cell death, including free radicals, proteases, inflammatory cytokines, and glutamate excitotoxicity. Proinflammatory cytokine release in MS is mediated in part by microglial activation. Takahashi et al. (2003) found that interleukin-1-beta (IL1B; 147720) and TNF-alpha, prominent microglia-derived cytokines, caused oligodendrocyte death in coculture with astrocytes and microglia, but not in pure culture of oligodendrocytes alone. Because IL1B had been shown to impair the activity of astrocytes in the uptake and metabolism of glutamate, Takahashi et al. (2003) hypothesized that the indirect toxic effect of microglia-derived IL1B and TNFA on oligodendrocytes involved increased glutamate excitotoxicity via modulation of astrocyte activity. In support, antagonists at glutamate receptors blocked the toxicity. The findings provided a mechanistic link between microglial activation in MS with glutamate-induced oligodendrocyte destruction.

    Steed et al. (2003) used structure-based design to engineer variant TNF proteins that rapidly form heterotrimers with native TNF to give complexes that neither bind to nor stimulate signaling through TNF receptors. Thus, TNF is inactivated by sequestration. Dominant-negative TNFs were thought to represent a possible approach to antiinflammatory biotherapeutics, and experiments in animal models showed that the strategy can attenuate TNF-mediated pathology.

    Using an integrated approach comprising tandem affinity purification, liquid chromatography tandem mass spectrometry, network analysis, and directed functional perturbation studies using RNA interference or loss-of-function analysis, Bouwmeester et al. (2004) identified 221 molecular associations and 80 previously unknown interactors, including 10 novel functional modulators, of the TNFA/NFKB signal transduction pathway.

    Kamata et al. (2005) found that TNF-alpha-induced reactive oxygen species (ROS), whose accumulation could be suppressed by mitochondrial superoxide dismutase (SOD2; 147460), caused oxidation and inhibition of JNK (see 601158)-inactivating phosphatases by converting their catalytic cysteine to sulfenic acid. This resulted in sustained JNK activation, which is required for cytochrome c (see 123995) release and caspase-3 (CASP3; 600636) cleavage, as well as necrotic cell death. Treatment of cells or experimental animals with an antioxidant prevented H2O2 accumulation, JNK phosphatase oxidation, sustained JNK activity, and both forms of cell death. Antioxidant treatment also prevented TNF-alpha-mediated fulminant liver failure without affecting liver regeneration.

    Membrane traffic in activated macrophages is required for 2 critical events in innate immunity: proinflammatory cytokine secretion and phagocytosis of pathogens. Murray et al. (2005) found a joint trafficking pathway linking both actions, which may economize membrane transport and augment the immune response. TNFA is trafficked from the Golgi to the recycling endosome, where vesicle-associated membrane protein-3 (VAMP3; 603657) mediates its delivery to the cell surface at the site of phagocytic cup formation. Fusion of the recycling endosome at the cup simultaneously allows rapid release of TNF-alpha and expands the membrane for phagocytosis.

    Using live-cell imaging, Lieu et al. (2008) showed that tubules and carriers expressing p230 (GOLGA4; 602509) selectively mediated TNF transport from the trans-Golgi network (TGN) in HeLa cells. LPS activation of macrophages caused a dramatic increase in p230-labeled tubules and carriers emerging from the TGN. Depletion of p230 in macrophages reduced cell surface delivery of TNF more than 10-fold compared with control cells. Mice with RNA interference-mediated silencing of p230 also had dramatically reduced surface expression of Tnf. Lieu et al. (2008) concluded that p230 is a key regulator of TNF secretion and that LPS activation of macrophages increases Golgi carriers for export.

    Stellwagen and Malenka (2006) showed that synaptic scaling in response to prolonged blockade of activity is mediated by the proinflammatory cytokine TNF-alpha. Using mixtures of wildtype and TNF-alpha-deficient neurons and glia, they showed that glia are the source of the TNF-alpha that is required for this form of synaptic scaling. Stellwagen and Malenka (2006) suggested that by modulating TNF-alpha levels, glia actively participate in the homeostatic activity-dependent regulation of synaptic connectivity.

    Kawane et al. (2006) showed that DNase II (see 126350)-null/interferon type I receptor (IFNIR)-null mice and mice with an induced deletion of the DNase II gene developed a chronic polyarthritis resembling human rheumatoid arthritis. A set of cytokine genes was strongly activated in the affected joints of these mice, and their serum contained high levels of anticyclic citrullinated peptide antibody, rheumatoid factor, and matrix metalloproteinase-3 (see 185250). Early in the pathogenesis, expression of the TNFA gene was upregulated in the bone marrow, and administration of anti-TNFA antibody prevented the development of arthritis. Kawane et al. (2006) concluded that if macrophages cannot degrade mammalian DNA from erythroid precursors and apoptotic cells, they produce TNFA, which activates synovial cells to produce various cytokines, leading to the development of chronic polyarthritis.

    Tay et al. (2010) used high-throughput microfluidic cell culture and fluorescence microscopy, quantitative gene expression analysis, and mathematical modeling to investigate how single mammalian cells respond to different concentrations of TNF-alpha and relay information to the gene expression programs by means of the transcription factor NF-kappa-B (see 164011). Tay et al. (2010) measured NF-kappa-B activity in thousands of live cells under TNF-alpha doses covering 4 orders of magnitude. They found that, in contrast to population-level studies with bulk assays, the activation was heterogeneous and was a digital process at the single-cell level with fewer cells responding at lower doses. Cells also encoded a subtle set of analog parameters, including NF-kappa-B peak intensity, response time, and number of oscillations, to modulate the outcome. Tay et al. (2010) developed a stochastic mathematical model that reproduced both the digital and analog dynamics, as well as most gene expression profiles, at all measured conditions, constituting a broadly applicable model for TNA-alpha-induced NF-kappa-B signaling in various types of cells.

    Francisella tularensis, the causative agent of tularemia and a potential biohazard threat, evades the immune response, including innate responses through the lipopolysaccharide receptor TLR4 (603030), thus increasing its virulence. Huang et al. (2010) deleted the bacterium's ripA gene and found that mouse macrophages and a human monocyte line produced significant amounts of the inflammatory cytokines TNF, IL18 (600953), and IL1B in response to the mutant. IL1B and IL18 secretion was dependent on PYCARD (606838) and CASP1 (147678), and MYD88 (602170) was required for inflammatory cytokine synthesis. A complemented strain with restored expression of ripA restored immune evasion, as well as activation of the MAP kinases ERK1 (MAPK3; 601795)/ERK2 (MAPK1; 176948), JNK, and p38 (MAPK14; 600289). Phamacologic inhibition of these MAPKs reduced cytokine induction by the ripA deletion mutant. Mice infected with the mutant exhibited stronger Il1b and Tnfa responses than mice infected with the wildtype live vaccine strain. Huang et al. (2010) concluded that the F. tularensis ripA gene product functions by suppressing MAPK pathways and cirmumventing the inflammasome response.

    - Role in Psoriasis

    Inflammatory cytokines such as TNF have been implicated in the pathogenesis of psoriasis (see 177900) (Bonifati and Ameglio, 1999). Leonardi et al. (2003) found that treatment with the TNF antagonist etanercept led to a significant reduction in the severity of psoriasis over a treatment period of 24 weeks.

    Boyman et al. (2004) engrafted keratome biopsies of human symptomless prepsoriatic skin onto AGR129 mice, which are deficient in type I and type II interferon receptors (see 107450 and 107470, respectively), as well as Rag2 (179616), and thereby lack B and T cells and show severely impaired NK cell activity. Upon engraftment, human T cells underwent local proliferation, which was crucial for development of a psoriatic phenotype exhibiting papillomatosis and acanthosis. Immunohistochemical analysis of prepsoriatic skin before transplantation and 8 weeks after transplantation showed activation of epidermal keratinocytes, dendritic cells, endothelial cells, and immune cells in the transplanted tissue. T-cell proliferation and the subsequent disease development were dependent on TNF production and could be inhibited by antibody or soluble receptor to TNF. Boyman et al. (2004) concluded that TNF-dependent activation of resident T cells is necessary and sufficient for development of psoriatic lesions.

    - Role in Rheumatoid Arthritis and Ankylosing Spondylitis

    TNF-alpha may play a part in the pathogenesis of ankylosing spondylitis (106300) and rheumatoid arthritis (RA; 180300). Gorman et al. (2002) tested the efficacy of inhibition of TNF-alpha in treatment of ankylosing spondylitis. They used etanercept, a dimeric fusion protein of the human 75-kD (p75) TNFR2 (TNFRSF1B; 191191) linked to the Fc portion of human IgG1 (147100). Treatment in 40 patients with active, inflammatory disease for 4 months resulted in rapid, significant, and sustained improvement.

    Nadkarni et al. (2007) had previously shown that anti-TNF (infliximab) therapy could overcome the inability of CD4 (186940)-positive/CD25 (IL2RA; 147730)-high regulatory T (Treg) cells from RA patients to suppress proinflammatory cytokine production by CD4-positive/CD25-negative T cells. Using flow cytometric analysis, they demonstrated that infliximab therapy induced a CD4-positive/CD25-high/FOXP3 (300292)-positive Treg population that mediated suppression via TGFB and IL10 and lacked expression of CD62L (SELL; 153240), a marker for CD4-positive/CD25-high/FOXP3-positive 'natural' Tregs. Natural Tregs remained defective in RA patients even after infliximab treatment. Nadkarni et al. (2007) concluded that anti-TNF therapy in RA patients induces a newly differentiated population of Tregs capable of restoring tolerance and compensating for defective natural Tregs.

    - Role in Tuberculosis

    Studies in mice (Flynn et al., 1995) and observations in patients receiving infliximab (remicade) for treatment of rheumatoid arthritis (180300) or Crohn disease (see IBD3; 604519) (Keane et al., 2001) have shown that antibody-mediated neutralization of TNF increases susceptibility to tuberculosis (TB; 607948). However, excess TNF may be associated with severe TB pathology (Barnes et al., 1990). Using path and segregation analysis and controlling for environmental differences, Stein et al. (2005) evaluated TNF secretion levels in Ugandan TB patients. The results suggested that there is a strong genetic influence, due to a major gene, on TNF expression in TB, and that there may be heterozygote advantage. The effect of shared environment on TNF expression in TB was minimal. Stein et al. (2005) concluded that TNF is an endophenotype for TB that may increase power to detect disease-predisposing loci.

    - Role in Autosomal Dominant Polycystic Kidney Disease

    Li et al. (2008) showed that TNF-alpha, which is found in cystic fluid of humans with autosomal dominant polycystic kidney disease (ADPKD; see 173900), disrupted the localization of polycystin-2 (PKD2; 173910) to the plasma membrane and primary cilia through TNF-alpha-induced scaffold protein FIP2 (OPTN; 602432). Treatment of mouse embryonic kidney organ cultures with TNF-alpha resulted in cyst formation, and this effect was exacerbated in Pkd2 +/- kidneys. TNF-alpha also stimulated cyst formation in vivo in Pkd2 +/- mice, and treatment of Pkd2 +/- mice with a TNF-alpha inhibitor prevented cyst formation.

    MOLECULAR GENETICS

    Single-nucleotide polymorphisms (SNPs) in regulatory regions of cytokine genes have been associated with susceptibility to a number of complex disorders. TNF is a proinflammatory cytokine that provides a rapid form of host defense against infection but is fatal in excess. Because TNF is employed against a variety of pathogens, each involving a different pattern of risks and benefits, it might be expected that this would favor diversity in the genetic elements that control TNF production.

    Herrmann et al. (1998) used PCR-SSCP and sequencing to screen the entire coding region and 1,053 bp upstream of the transcription start site of the TNFA gene for polymorphisms. Five polymorphisms were identified: 4 were located in the upstream region at positions -857, -851, -308 (191160.0004), and -238 from the first transcribed nucleotide, and 1 was found in a nontranslated region at position +691.

    Three SNPs located at nucleotides -238, -308, and -376 (191160.0003) with respect to the TNF transcriptional start site are all substitutions of adenine for guanine. Knight et al. (1999) referred to the allelic types as -238G/-238A, -308G/-308A, and -376G/-376A. They stated that variation in the TNFA promoter region had been found to be associated with susceptibility to cerebral malaria (McGuire et al., 1994), with mucocutaneous leishmaniasis (Cabrera et al., 1995), with death from meningococcal disease (Nadel et al., 1996), with lepromatous leprosy (Roy et al., 1997), with scarring trachoma (Conway et al., 1997), and with asthma (Moffatt and Cookson, 1997).

    Flori et al. (2003) tested for linkage between polymorphisms within the MHC region and mild malaria; see 609148. Two-point analysis indicated linkage of mild malaria to TNFd (lod = 3.27), a highly polymorphic marker in the MHC region. Multipoint analysis also indicated evidence for linkage of mild malaria to the MHC region, with a peak close to TNF (lod = 3.86). The authors proposed that genetic variation within TNF may influence susceptibility to mild malaria, but the polymorphisms TNF-238, TNF-244, and TNF-308 (191160.0004) are unlikely to explain linkage of mild malaria to the MHC region.

    Statistical analyses by Funayama et al. (2004) showed a possible interaction between polymorphisms in the optineurin (OPTN; 602432) and TNF genes that would increase the risk for the development and probably progression of glaucoma in Japanese patients with POAG (137760).

    By sequencing the promoter regions 500 bp upstream from the transcriptional start sites of members of the TNF and TNFR superfamilies, Kim et al. (2005) identified 23 novel regulatory SNPs in Korean donors. Sequence analysis suggested that 9 of the SNPs altered putative transcription factor binding sites. Analysis of SNP databases suggested that the SNP allele frequencies were similar to those for Japanese subjects but distinct from those of Caucasian or African populations.

    - Insulin Resistance and Diabetes

    Zinman et al. (1999) studied the relationship between TNF-alpha and anthropometric and physiologic variables associated with insulin resistance and diabetes in an isolated Native Canadian population with very high rates of NIDDM (125853). Using the homeostasis assessment (HOMA) model to estimate insulin resistance, they found moderate, but statistically significant, correlations between TNF-alpha and fasting insulin, HOMA insulin resistance, waist circumference, fasting triglycerides, and systolic blood pressure; in all cases, coefficients for females were stronger than those for males. The authors concluded that in this homogeneous Native Canadian population, circulating TNF-alpha concentrations were positively correlated with insulin resistance across a spectrum of glucose tolerance. The data suggested a possible role for TNF-alpha in the pathophysiology of insulin resistance.

    Rasmussen et al. (2000) investigated whether the -308 and -238 G-to-A genetic variants of TNF were associated with features of the insulin resistance syndrome or alterations in birth weight in 2 Danish study populations comprising 380 unrelated young healthy subjects and 249 glucose-tolerant relatives of type 2 diabetic patients, respectively. Neither of the variants was related to altered insulin sensitivity index or other features of the insulin resistance syndrome. Birth weight and the ponderal index were also not associated with the polymorphisms. Their study did not support a major role of the -308 or -238 substitutions in TNF in the pathogenesis of insulin resistance or altered birth weight among Danish Caucasian subjects.

    Obayashi et al. (2000) investigated the influence of TNF-alpha on the predisposition to insulin dependency in adult-onset diabetic patients with type I diabetes (IDDM; 222100)-protective HLA haplotypes. Also see HLA-DQB1 (604305). The TNF-alpha of 3 groups of DRB1*1502-DQB1*0601-positive diabetic patients who had initially been nonketotic and noninsulin dependent for more than 1 year was analyzed. Group A included 11 antibodies to glutamic acid decarboxylase (GADab)-positive patients who developed insulin dependency within 4 years of diabetes onset. Group B included 11 GADab-positive patients who remained noninsulin dependent for more than 12 years. Group C included 12 GADab-negative type 2 diabetes, and a control group included 18 nondiabetic subjects. In the group C and control subjects, DRB1*1502-DQB1*0601 was strongly associated with the TNFA-13 allele. DRB1*1502-DQB1*0601 was strongly associated with the TNFA-12 allele among the group A patients, but not among the group B patients. Interestingly, sera from all patients with non-TNFA-12 and non-TNFA-13 in group B reacted with GAD65 protein by Western blot. The authors concluded that TNF-alpha is associated with a predisposition to progression to insulin dependency in GADab/DRB1*1502-DQB1*0601-positive diabetic patients initially diagnosed with type II diabetes and that determination of these patients' TNF-alpha genotype may allow for better prediction of their clinical course.

    To study whether the TNFA gene could be a modifying gene for diabetes, Li et al. (2003) studied TNFA promoter polymorphisms (G-to-A substitution at positions -308 and -238) in relation to HLA-DQB1 genotypes in type 2 diabetes patients from families with both type 1 and type 2 diabetes (type 1/2 families) or common type 2 diabetes families as well as in patients with adult-onset type 1 diabetes and control subjects. The TNFA(308) AA/AG genotype frequency was increased in adult-onset type 1 patients (55%, 69 of 126), but it was similar in type 2 patients from type 1/2 families (35%, 33/93) or common type 2 families (31%, 122 of 395), compared with controls (33%, 95/284; P less than 0.0001 vs type 1). The TNFA(308) A and DQB1*02 alleles were in linkage disequilibrium in type 1 patients (Ds = 0.81; P less than 0.001 vs Ds = 0.25 in controls) and type 2 patients from type 1/2 families (Ds = 0.59, P less than 0.05 vs controls) but not in common type 2 patients (Ds = 0.39). The polymorphism was associated with an insulin-deficient phenotype in type 2 patients from type 1/2 families only together with DQB*02, whereas the common type 2 patients with AA/AG had lower waist-to-hip ratio 0.92 (0.12) vs 0.94 (0.11), P = 0.008] and lower fasting C-peptide concentration 0.48 (0.47) vs 0.62 (0.46) nmol/liter, P = 0.020] than those with GG, independently of the presence of DQB1*02. The authors concluded that TNFA is unlikely to be the second gene on the short arm of chromosome 6 responsible for modifying the phenotype of type 2 diabetic patients from families with both type 1 and type 2 diabetes.

    Shbaklo et al. (2003) evaluated TNFA promoter polymorphisms at positions -863 (191160.0006) and -1031 and their association with type 1 diabetes in a group of 210 diabetic patients in Lebanon. Their results showed that in that population, the C allele is predominant at position -863, whereas the A allele is rare (2%). At position -1031, however, the C and T allele distribution was similar in both the patient (17.8% vs 82.2%, respectively) and the control (21.4% vs 79.6%) groups. No association of TNFA genotype at position 1031 with type 1 diabetes was found as demonstrated by the family-based association test and the transmission disequilibrium test. However, when patient genotypes were compared, the recessive CC genotype was found in type 1 diabetic males but not in type 1 diabetic females.

    - Coronary Heart Disease

    From studies of 641 patients with myocardial infarction and 710 control subjects, Herrmann et al. (1998) concluded that polymorphisms of the TNFA gene are unlikely to contribute to coronary heart disease risk in an important way, but that the -308 mutation should be investigated further in relation to obesity.

    - Obesity

    Because TNF-alpha expression had been reported to be increased in adipose tissue of both rodent models of obesity and obese humans, TNFA was considered a candidate gene for obesity (see 601665). Norman et al. (1995) scored Pima Indians for genotypes at 3 polymorphic dinucleotide repeat loci near the TNFA gene. In a sib-pair linkage analysis, the percentage of body fat, as measured by hydrostatic weighing, was linked (304 sib pairs, P = 0.002) to the marker closest (10 kb) to TNFA. The same marker was associated (P = 0.01) by analysis of variants with body mass index (BMI). To search for DNA variants in TNFA possibly contributing to obesity, they performed SSCP analysis on the gene from 20 obese and 20 lean subjects. No association could be demonstrated between alleles at the single polymorphism located in the promoter region and percent of body fat.

    Rosmond et al. (2001) examined the potential impact of the G-to-A substitution at position -308 of the TNFA gene promoter on obesity and estimates of insulin, glucose, and lipid metabolism as well as circulating hormones including salivary cortisol in 284 unrelated Swedish men born in 1944. Genotyping revealed allele frequencies of 0.77 for allele G and 0.23 for allele A. Tests for differences in salivary cortisol levels between the TNFA genotypes revealed that, in homozygotes for the rare allele in comparison with the other genotypes, there were significantly higher cortisol levels in the morning, before as well as 30 and 60 minutes after stimulation by a standardized lunch. In addition, homozygotes for the rare allele had a tendency toward higher mean values of body mass index, waist-to-hip ratio, and abdominal sagittal diameter compared with the other genotype groups. The results also indicated a weak trend toward elevated insulin and glucose levels among men with the A/A genotype. Rosmond et al. (2001) suggested that the increase in cortisol secretion associated with this polymorphism might be the endocrine mechanism underlying the previously observed association between the NcoI TNFA polymorphism and obesity, as well as insulin resistance.

    - Hyperandrogenism

    To evaluate the role of TNF-alpha in the pathogenesis of hyperandrogenism, Escobar-Morreale et al. (2001) evaluated the serum TNF-alpha levels, as well as several polymorphisms in the promoter region of the TNF-alpha gene, in a group of 60 hyperandrogenic patients and 27 healthy controls matched for body mass index. Hyperandrogenic patients presented with mildly increased serum TNF-alpha levels as compared with controls. When subjects were classified by body weight, serum TNF-alpha was increased only in lean patients as compared with lean controls; this difference was not statistically significant when comparing obese patients with obese controls. The TNF-alpha gene polymorphisms studied were equally distributed in hyperandrogenic patients and controls. However, carriers of the -308A variant presented with increased basal and leuprolide-stimulated serum androgens and 17-hydroxyprogesterone levels when considering patients and controls as a group. The authors concluded that the TNF-alpha system might contribute to the pathogenesis of hyperandrogenism.

    - Septic Shock

    De Groof et al. (2002) evaluated the GH (see 139250)/IGF1 (147440) axis and the levels of IGF-binding proteins (IGFBPs), IGFBP3 protease (146732), glucose, insulin (176730), and cytokines in 27 children with severe septic shock due to meningococcal sepsis during the first 3 days after admission. The median age was 22 months. Nonsurvivors had extremely high GH levels that were significantly different compared with mean GH levels in survivors during a 6-hour GH profile. Significant differences were found between nonsurvivors and survivors for the levels of total IGF1, free IGF1, IGFBP1, IGFBP3 protease activity, IL6 (147620), and TNFA. The pediatric risk of mortality score correlated significantly with levels of IGFBP1, IGFBP3 protease activity, IL6, and TNFA and with levels of total IGF1 and free IGF1. Levels of GH and IGFBP1 were extremely elevated in nonsurvivors, whereas total and free IGF1 levels were markedly decreased and were accompanied by high levels of the cytokines IL6 and TNFA.

    Mira et al. (1999) reported the results of a multicenter case-control study of the frequency of the -308G-A polymorphism, which they called the TNF2 allele, in patients with septic shock. Eighty-nine patients with septic shock and 87 healthy unrelated blood donors were studied. Mortality among patients with septic shock was 54%. The polymorphism frequencies of the controls and patients differed only at the TNF2 allele (39% vs 18% in the septic shock and control groups, respectively, P = 0.002). Among the septic shock patients, TNF2 polymorphism frequency was significantly greater among those who had died (52% vs 24% in the survival group, P = 0.008). Concentrations of TNF-alpha were higher with TNF2 (68%) than with TNF1 (52%), but their median values were not statistically different. Mira et al. (1999) estimated that patients with the TNF2 allele had a 3.7-fold risk of death.

    - Cerebral Malaria

    Because fatal cerebral malaria is associated with high circulating levels of tumor necrosis factor-alpha, McGuire et al. (1994) undertook a large case-control study in Gambian children. The study showed that homozygotes for the TNF2 allele, a variant of the TNFA gene promoter region (Wilson et al., 1992), had a relative risk of 7 for death or severe neurologic sequelae due to cerebral malaria. Although the TNF2 allele is in linkage disequilibrium with several neighboring HLA alleles, McGuire et al. (1994) showed that this disease association was independent of HLA class I and class II variation. The data suggested that regulatory polymorphisms of cytokine genes can affect the outcome of severe infection. The maintenance of the TNF2 allele at a gene frequency of 0.16 in The Gambia implies that the increased risk of cerebral malaria in homozygotes is counterbalanced by some biologic advantage.

    Hill (1999) reviewed the genetic basis of susceptibility and resistance to malaria, and tabulated 10 genes that are known to affect susceptibility or resistance to Plasmodium falciparum and/or Plasmodium vivax. He noted that the association of an upregulatory variant of the TNF gene promoter (Wilson et al., 1997) with cerebral malaria (McGuire et al., 1994) had encouraged the assessment of agents that might reduce the activity of this cytokine (van Hensbroek et al., 1996).

    Through systematic DNA fingerprinting of the TNF promoter region, Knight et al. (1999) identified a SNP that causes the helix-turn-helix transcription factor OCT1 (POU2F1; 164175) to bind to a novel region of complex protein-DNA interactions and alters gene expression in human monocytes. The OCT1-binding genotype, found in approximately 5% of Africans, was associated with 4-fold increased susceptibility to cerebral malaria in large studies comparing cases and controls in West African and East African populations, after correction for other known TNF polymorphisms and linked HLA alleles. See 191160.0003.

    - Alopecia Areata

    Galbraith and Pandey (1995) studied 2 polymorphic systems of tumor necrosis factor-alpha in 50 patients with alopecia areata (104000). The first biallelic TNFA polymorphism was detected in humans by Wilson et al. (1992); this involved a single base change from G to A at position -308 in the promoter region of the gene (191160.0004). The less common allele, A at -308 (called T2), shows an increased frequency in patients with IDDM, but this depends on the concurrent increase in HLA-DR3 with which T2 is associated. A second TNFA polymorphism, described by D'Alfonso and Richiardi (1994), also involves a G-to-A transition at position -238 of the gene. In alopecia areata, Galbraith and Pandey (1995) found that the distribution of T1/T2 phenotypes differed between patients with the patchy form of the disease and patients with totalis/universalis disease. There was no significant difference in the distribution of the phenotypes for the second system. The results suggested genetic heterogeneity between the 2 forms of alopecia areata and suggested that the TNFA gene is a closely linked locus within the major histocompatibility complex on chromosome 6 where this gene maps and may play a role in the pathogenesis of the patchy form of the disease.

    - Rheumatoid Arthritis

    Mulcahy et al. (1996) determined the inheritance of 5 microsatellite markers from the TNF region in 50 multiplex rheumatoid arthritis (RA; 180300) families. Overall, 47 different haplotypes were observed. One of these was present in 35.3% of affected, but in only 20.5% of unaffected, individuals (P less than 0.005). This haplotype accounted for 21.5% of the parental haplotypes transmitted to affected offspring and only 7.3% of the haplotypes not transmitted to affected offspring (P = 0.0003). Further study suggested that the tumor necrosis factor--lymphotoxin (TNF-LT) region influences susceptibility to RA, distinct from HLA-DR. The study illustrated the use of the transmission disequilibrium test (TDT) as described by Spielman et al. (1993).

    - Osteoporosis and Osteopenia

    Ota et al. (2000) tested 192 sib pairs of adult Japanese women from 136 families for genetic linkage between osteoporosis and osteopenia phenotypes and allelic variants at the TNFA locus, using a dinucleotide repeat polymorphism located near the gene. The TNFA locus showed evidence for linkage to osteoporosis, with mean allele sharing of 0.478 (P = 0.30) in discordant pairs and 0.637 (P = 0.001) in concordant affected pairs. Linkage with osteopenia was also significant in concordant affected pairs (P = 0.017). Analyses limited to the postmenopausal women in their cohort showed similar or even stronger linkage for both phenotypes.

    - Asthma

    Winchester et al. (2000) studied the association of the -308G-A variant of the TNFA gene and the insertion/deletion variant of angiotensin-converting enzyme (ACE; 106180) with a self-reported history of childhood asthma in 2 population groups. The -308A allele was significantly associated with self-reported childhood asthma in the UK/Irish population but not in the South Asian population. The ACE DD genotype was not associated with childhood asthma in either population. Thus, either the -308A allele or a linked major histocompatibility complex variant may be a genetic risk factor for childhood asthma in the UK/Irish sample.

    - Inflammatory Bowel Diseases

    Koss et al. (2000) found that women but not men with extensive compared to distal colitis (see IBD3, 604519) were significantly more likely to bear the -308G-A promoter polymorphism of the TNF gene (191160.0004). The association was even stronger in women who also had an A rather than a C at position 720 in the LTA gene (153440). These polymorphisms were also associated with significantly higher TNF production in patients with Crohn disease, whereas an A instead of a G at position -238 in the TNF gene was associated with lower production of TNF in patients with ulcerative colitis.

    For additional discussion of an association between variation in the TNF gene and inflammatory bowel disease, see IBD3 (604519).

    - Hepatitis B

    To investigate whether TNF-alpha promoter polymorphisms are associated with clearance of hepatitis B virus (HPV) infection, Kim et al. (2003) genotyped 1,400 Korean subjects, 1,109 of whom were chronic HBV carriers and 291 who spontaneously recovered. The TNF promoter alleles that were previously reported to be associated with higher plasma levels (presence of -308A or the absence of -863A alleles), were strongly associated with the resolution of HBV infection. Haplotype analysis revealed that TNF-alpha haplotype 1 (-1031T; -863C; -857C; -308G; -238G; -163G) and haplotype 2 (-1031C; -863A; -857C; -308G; -238G; -163G) were significantly associated with HBV clearance, showing protective antibody production and persistent HBV infection, respectively (P = 0.003-0.02).

    - Cystic Fibrosis

    Buranawuti et al. (2007) determined the TNF-alpha-238 and -308 genotypes in 3 groups of patients with cystic fibrosis (CF; 219700): 101 children under 17 years of age, 115 adults, and 38 nonsurviving adults (21 deceased and 17 lung transplant after 17 years of age). Genotype frequencies among adults and children with CF differed for TNF-alpha-238 (G/G vs G/A, p = 0.022), suggesting that TNF-alpha-238 G/A is associated with an increased chance of surviving beyond 17 years of age. When adults with CF were compared to nonsurviving adults with CF, genotype frequencies again differed (TNF-alpha 238 G/G vs G/A, p = 0.0015), and the hazard ratio for TNF-alpha-238 G/G versus G/A was 0.25. Buranawuti et al. (2007) concluded that the TNF-alpha-238 G/A genotype appears to be a genetic modifier of survival in patients with CF.

    - Role in HLA-B27-Associated Uveitis

    In a study of 114 Caucasian patients with HLA-B27-associated uveitis compared with 63 healthy unrelated HLA-B27-positive blood donors and 88 healthy unrelated HLA-B27-negative individuals, El-Shabrawi et al. (2006) found that the frequencies of the TNF-alpha -308GA and -238GA genotypes were significantly lower in patients with HLA-B27-associated uveitis (6.1% and 0%, respectively) when compared with the HLA-B27-negative group, 23% at -308 (p = 0.003), and 7.9% at -238 (p = 0.0003). The frequency of the -238GA genotype was also significantly lower in patients than among the healthy HLA-B27-positive group. The authors concluded that HLA-B27-positive individuals show a higher susceptibility towards development of intraocular inflammation in the presence of an A allele at nucleotide -238, and to a lesser degree, at nucleotide -308 of the TNF-alpha gene promoter.

    GENE STRUCTURE

    Nedwin et al. (1985) determined that TNFA and LTA genes have similar structures; each spans about 3 kb and contains 4 exons. Only the last exons of these genes, which code more than 80% of the secreted protein, are significantly homologous (56%).

    MAPPING

    By analysis of human-mouse somatic cell hybrids, Nedwin et al. (1985) found that TNFA and TNFB are closely linked on chromosome 6. Study of hybrid cells made with rearranged human chromosome 6 showed that both TNFA and TNFB map to the 6p23-q12 segment. Nedwin et al. (1985) speculated that close situation of these 2 loci to HLA 'may be useful for a coordinate regulation of immune system gene products.' By Southern blot analysis of a panel of major histocompatibility complex deletion mutants, Spies et al. (1986) established that TNFA and TNFB are closely linked and situated in the MHC either between HLA-DR (see 142860) and HLA-A (142800) or centromeric of HLA-DP (see 142858). By in situ hybridization, they assigned TNFA and TNFB to 6p21.3-p21.1. By pulsed field gel electrophoresis, Carroll et al. (1987) showed that the TNF genes are located 200 kb centromeric of HLA-B (142830) and about 350 kb telomeric of the class I cluster. The TNFA and TNFB genes are separated by 1 to 2 kb of DNA. By hybridization to fragments of NruI-digested DNA, Ragoussis et al. (1988) demonstrated that the TNFA/TNFB genes lie between C2 of class III and HLA-B of class I.

    Nedospasov et al. (1986) showed that, in the mouse, TNFA and TNFB are likewise tandemly arranged and situated on chromosome 17, which bears much homology of synteny with chromosome 6 of man. Muller et al. (1987) mapped both tumor necrosis factor and lymphotoxin close to H-2D in the mouse major histocompatibility complex on chromosome 14. By pulsed field gel electrophoresis, Inoko and Trowsdale (1987) showed that the human TNFA and TNFB genes are linked to the HLA-B locus, analogous to their position in the mouse, where they are located between the class III region and H-2D. However, the distance between the TNF genes and the class I region was much greater in man, namely, about 260 kb, compared to 70 kb in the mouse.

    As noted, the region spanning the tumor necrosis factor (TNF) cluster in the human major histocompatibility complex (MHC) has been implicated in susceptibility to numerous immunopathologic diseases, including type 1 diabetes mellitus (IDDM; 222100) and rheumatoid arthritis (180300). However, strong linkage disequilibrium across the MHC has hampered the identification of the precise genes involved. In addition, the observation of 'blocks' of DNA in the MHC within which recombination is very rare limits the resolution that may be obtained by genotyping individual SNPs. To gain a greater understanding of the haplotypes of the block spanning the TNF cluster, Allcock et al. (2004) genotyped 32 HLA-homozygous cell lines and 300 healthy control samples for 19 coding and promoter region SNPs spanning 45 kb in the central MHC near the TNF genes. The workshop cell lines defined 11 SNP haplotypes that account for approximately 80% of the haplotypes observed in the 300 control individuals. Using the control individuals, they defined a further 6 haplotypes that account for an additional 10% of donors. They showed that the 17 haplotypes of the 'TNF block' can be identified using 15 SNPs.

    The TNF block studied by Allcock et al. (2004) includes the TNF genes (TNFA; LTA, 153440; and LTB, 600978), as well as AIF1 (601833), the activating NK receptor NCR3 (611550), NFKBIL1 (601022), ATP6P1G (606853), and BAT1 (142560).

    HISTORY

    Old (1985) recounted the series of observations, experiments and discoveries that led up to definition of human TNF and cloning of the gene. He referred to cloning as 'an important rite of passage for biological factors such as TNF, and there is a growing sense that a factor has to be cloned before it is taken very seriously.' He paraphrased Descartes: 'It's been cloned, therefore it exists.'

    Feldmann and Maini (2010) reviewed the findings that led to targeting of TNF in the treatment of rheumatoid arthritis and other chronic diseases and offered an appreciation of the role of cytokines in medicine.

    ANIMAL MODEL

    Bruce et al. (1996) used targeted gene disruption to generate mice lacking either the p55 (TNFRSF1A; 191190) or the p75 TNF receptors; mice lacking both p55 and p75 were generated from crosses of the singly deficient mice. The TNFR-deficient (TNFR-KO) mice exhibited no overt phenotype under unchallenged conditions. Bruce et al. (1996) reported that damage to neurons caused by focal cerebral ischemia and epileptic seizures was exacerbated in the TNFR-KO mice, indicating that TNF serves a neuroprotective function. Their studies indicated that TNF protects neurons by stimulating antioxidative pathways. Injury-induced microglial activation was suppressed in TNFR-KO mice. They concluded that drugs which target TNF signaling pathways may prove beneficial in treating stroke or traumatic brain injury.

    Marino et al. (1997) generated knockout mice deficient in TNF and characterized the response of these mice to a variety of inflammatory, infectious, and antigenic stimuli.

    Uysal et al. (1997) generated obese mice with a targeted null mutation in the genes for Tnf and its p55 and p75 receptors. The absence of TNF resulted in significantly improved insulin sensitivity in both diet-induced obesity and the ob/ob (see 164160) model of obesity. Tnf-deficient mice had lower levels of circulating free fatty acids and were protected from the obesity-related reduction in insulin receptor signaling in muscle and fat tissues. Uysal et al. (1997) concluded that TNF is an important mediator of insulin resistance in obesity through its effects on several important sites of insulin action.

    Roach et al. (2002) noted that TNF is essential for the formation and maintenance of granulomas and for resistance against infection with Mycobacterium tuberculosis. Mice lacking Tnf mount a delayed chemokine response associated with a delayed cellular infiltrate. Subsequent excessive chemokine production and an intense but loose and undifferentiated cluster of T cells and macrophages, capable of producing high levels of Ifng in vitro, were unable to protect Tnf -/- mice from fatal tuberculosis after approximately 28 days, whereas all wildtype mice survived for at least 16 weeks. Roach et al. (2002) concluded that TNF is required for the early induction of chemokine production and the recruitment of cells forming a protective granuloma. The TNF-independent production of chemokines results in a dysregulated inflammatory response unable to contain M. tuberculosis, which suggests a mechanism for the reactivation of clinical tuberculosis observed by Keane et al. (2001) in patients undergoing treatment for rheumatoid arthritis (180300) or Crohn disease (see 266600) with a humanized monoclonal antibody to TNF.

    Diwan et al. (2004) compared transgenic mice with targeted cardiac overexpression of secreted wildtype Tnf to transgenic mice with targeted cardiac overexpression of a noncleavable transmembrane form of Tnf. Both lines of mice had overlapping levels of myocardial Tnf protein, but developed strikingly different cardiac phenotypes: the mice overexpressing the transmembrane form of Tnf developed concentric left ventricular hypertrophy, whereas the mice overexpressing secreted Tnf had dilated left ventricular hypertrophy. Diwan et al. (2004) suggested that posttranslational processing of TNF by ADAM17 (603639), as opposed to TNF expression per se, is responsible for the adverse cardiac remodeling that occurs after sustained TNF overexpression.

    Vielhauer et al. (2005) studied immune complex-mediated glomerulonephritis in Tnfr1- and Tnfr2-deficient mice. Proteinuria and renal pathology were initially milder in Tnfr1-deficient mice, but at later time points were similar to those in wildtype controls, with excessive renal T-cell accumulation and reduced T-cell apoptosis. In contrast, Tnfr2-deficient mice were completely protected from glomerulonephritis at all time points, despite an intact immune system response. Tnfr2 expression on intrinsic renal cells, but not leukocytes, was essential for glomerulonephritis and glomerular complement deposition. Vielhauer et al. (2005) concluded that the proinflammatory and immunosuppressive properties of TNF segregate at the level of its receptors, with TNFR1 promoting systemic immune responses and renal T-cell death and intrinsic renal cell TNFR2 playing a critical role in complement-dependent tissue injury.

    In mice, Balosso et al. (2005) found that intrahippocampal injection of murine Tnfa or astrocytic overexpression of murine Tnfa inhibited the number and duration of kainate-induced seizures. Transgenic mice lacking p75 receptors showed increased seizure susceptibility, suggesting that the protective effect of Tnfa was mediated by p75 receptors. Immunohistochemical and Western blot analysis identified p75 receptors, but not p55 receptors, in the mouse hippocampus. The findings indicated a role for inflammatory pathways in the pathophysiology of seizures.

    Both homozygous and heterozygous Tshr (603372)-null mice are osteopenic with evidence of enhanced osteoclast differentiation. Hase et al. (2006) found that increased osteoclastogenesis in these mice was rescued with graded reductions in the dosage of the Tnf gene.

    Soller et al. (2007) reported that canine Tnf, Il1a (147760), and Il1b (147720) have high coding and protein sequence identity to human and other mammalian homologs. They suggested that dog models of cytokine-mediated human diseases may be highly informative.

    Guo et al. (2008) noted that transgenic mice overexpressing human TNF exhibit reduced long bone volume, decreased mineralized bone nodule formation, and arthritis. They showed that TNF overexpression induced bone loss by increasing expression of Smurf1 (605568), resulting in ubiquitination and proteasomal degradation of Smad1 (601595) and Runx2 (600211). Deletion of Smurf1 in TNF-transgenic mice prevented systemic bone loss and improved bone strength.
    REFERENCES
    1. Aggarwal, B. B.; Eessalu, T. E.; Hass, P. E.
      Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.
      Nature 318 665-667 (1985)
    2. Allcock, R. J. N.; Windsor, L.; Gut, I. G.; Kucharzak, R.; Sobre, L.; Lechner, D.; Garnier, J.-G.; Baltic, S.; Christiansen, F. T.; Price, P.
      High-density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging.
      Hum. Mutat. 24 517-525 (2004)
    3. Aoki, T.; Hirota, T.; Tamari, M.; Ichikawa, K.; Takeda, K.; Arinami, T.; Shibasaki, M.; Noguchi, E.
      An association between asthma and TNF-308G/A polymorphism: meta-analysis.
      J. Hum. Genet. 51 677-685 (2006)
    4. Balding, J.; Kane, D.; Livingstone, W.; Mynett-Johnson, L.; Bresnihan, B.; Smith, O.; FitzGerald, O.
      Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity.
      Arthritis Rheum. 48 1408-1413 (2003)
    5. Balosso, S.; Ravizza, T.; Perego, C.; Peschon, J.; Campbell, I. L.; De Simoni, M. G.; Vezzani, A.
      Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors.
      Ann. Neurol. 57 804-812 (2005)
    6. Barnes, P. F.; Fong, S. J.; Brennan, P. J.; Twomey, P. E.; Mazumder, A.; Modlin, R. L.
      Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis.
      J. Immun. 145 149-154 (1990)
    7. Beattie, E. C.; Stellwagen, D.; Morishita, W.; Bresnahan, J. C.; Ha, B. K.; Von Zastrow, M.; Beattie, M. S.; Malenka, R. C.
      Control of synaptic strength by glial TNF-alpha.
      Science 295 2282-2285 (2002)
    8. Beutler, B.; Krochin, N.; Milsark, I. W.; Luedke, C.; Cerami, A.
      Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.
      Science 232 977-980 (1986)
    9. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. F.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Nelson, N.; Boiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P.
      A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.
      Nature 385 729-733 (1997)
    10. Bonifati, C.; Ameglio, F.
      Cytokines in psoriasis.
      Int. J. Derm. 38 241-251 (1999)
    11. Bouwmeester, T.; Bauch, A.; Ruffner, H.; Angrand, P.-O.; Bergamini, G.; Croughton, K.; Cruciat, C.; Eberhard, D.; Gagneur, J.; Ghidelli, S.; Hopf, C.; Huhse, B.; and 16 others
      A physical and functional map of the human TNF-alpha/NF-kappa-B signal transduction pathway.
      Nature Cell Biol. 6 97-105 (2004)
    12. Boyman, O.; Hefti, H. P.; Conrad, C.; Nickoloff, B. J.; Suter, M.; Nestle, F. O.
      Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha.
      J. Exp. Med. 199 731-736 (2004)
    13. Brenner, D. A.; O'Hara, M.; Angel, P.; Chojkier, M.; Karin, M.
      Prolonged activation of JUN and collagenase genes by tumour necrosis factor-alpha.
      Nature 337 661-663 (1989)
    14. Broudy, V. C.; Kaushansky, K.; Segal, G. M.; Harlan, J. M.; Adamson, J. W.
      Tumor necrosis factor type alpha stimulates human endothelial cells to produce granulocyte/macrophage colony-stimulating factor.
      Proc. Nat. Acad. Sci. 83 7467-7471 (1986)
    15. Bruce, A. J.; Boling, W.; Kindy, M. S.; Peschon, J.; Kraemer, P. J.; Carpenter, M. K.; Holtsberg, F. W.; Mattson, M. P.
      Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors.
      Nature Med. 2 788-794 (1996)
    16. Buranawuti, K.; Boyle, M. P.; Cheng, S.; Steiner, L. L.; McDougal, K.; Fallin, M. D.; Merlo, C.; Zeitlin, P. L.; Rosenstein, B. J.; Mogayzel, P. J., Jr.; Wang, X.; Cutting, G. R.
      Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosis.
      J. Med. Genet. 44 209-214 (2007)
    17. Cabrera, M.; Shaw, M. A.; Sharples, C.; Williams, H.; Castes, M.; Convit, J.; Blackwell, J. M.
      Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis.
      J. Exp. Med. 182 1259-1264 (1995)
    18. Carroll, M. C.; Katzman, P.; Alicot, E. M.; Koller, B. H.; Geraghty, D. E.; Orr, H. T.; Strominger, J. L.; Spies, T.
      Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes.
      Proc. Nat. Acad. Sci. 84 8535-8539 (1987)
    19. Conway, D. J.; Holland, M. J.; Bailey, R. L.; Campbell, A. E.; Mahdi, O. S.; Jennings, R.; Mbena, E.; Mabey, D. C.
      Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid.
      Infect. Immun. 65 1003-1006 (1997)
    20. Cox, A.; Gonzalez, A. M.; Wilson, A. G.; Wilson, R. M.; Ward, J. D.; Artlett, C. M.; Welsh, K.; Duff, G. W.
      Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM.
      Diabetologia 37 500-503 (1994)
    21. D'Alfonso, S.; Richiardi, P. M.
      A polymorphic variation in a putative regulation box of the TNFA promoter region.
      Immunogenetics 39 150-154 (1994)
    22. Davis, J. M.; Narachi, M. A.; Alton, N. K.; Arakawa, T.
      Structure of human tumor necrosis factor alpha derived from recombinant DNA.
      Biochemistry 26 1322-1326 (1987)
    23. De Groof, F.; Joosten, K. F. M.; Janssen, J. A. M. J. L.; De Kleijn, E. D.; Hazelzet, J. A.; Hop, W. C. J.; Uitterlinden, P.; Van Doorn, J.; Hokken-Koelega, A. C. S.
      Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors.
      J. Clin. Endocr. Metab. 87 3118-3124 (2002)
    24. Diwan, A.; Dibbs, Z.; Nemoto, S.; DeFreitas, G.; Carabello, B. A.; Sivasubramanian, N.; Wilson, E. M.; Spinale, F. G.; Mann, D. L.
      Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes.
      Circulation 109 262-268 (2004)
    25. El-Shabrawi, Y.; Wegscheider, B. J.; Weger, M.; Renner, W.; Posch, U.; Ulrich, S.; Ardjomand, N.; Hermann, J.
      Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HHA-B-27-associated uveitis: association with susceptibility and clinical manifestations.
      Ophthalmology 113 695-700 (2006)
    26. Escobar-Morreale, H. F.; Calvo, R. M.; Sancho, J.; San Millan, J. L.
      TNF-alpha and hyperandrogenism: a clinical, biochemical, and molecular genetic study.
      J. Clin. Endocr. Metab. 86 3761-3767 (2001)
    27. Feldmann, M.; Maini, R. N.
      Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?
      J. Immun. 185 791-794 (2010)
    28. Flori, L.; Sawadogo, S.; Esnault, C.; Delahaye, N. F.; Fumoux, F.; Rihet, P.
      Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso.
      Hum. Molec. Genet. 12 375-378 (2003)
    29. Flynn, J. L.; Goldstein, M. M.; Chan, J.; Triebold, K. J.; Pfeffer, K.; Lowenstein, C. J.; Schreiber, R.; Mak, T. W.; Bloom, B. R.
      Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.
      Immunity 2 561-572 (1995)
    30. Fowler, E. V.; Eri, R.; Hume, G.; Johnstone, S.; Pandeya, N.; Lincoln, D.; Templeton, D.; Radford-Smith, G. L.
      TNF-alpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease.
      (Letter) J. Med. Genet. 42 523-528 (2005)
    31. Franchimont, D.; Martens, H.; Hagelstein, M.-T.; Louis, E.; Dewe, W.; Chrousos, G. P.; Belaiche, J.; Geenen, V.
      Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor.
      J. Clin. Endocr. Metab. 84 2834-2839 (1999)
    32. Funayama, T.; Ishikawa, K.; Ohtake, Y.; Tanino, T.; Kurasaka, D.; Kimura, I.; Suzuki, K.; Ideta, H.; Nakamoto, K.; Yasuda, N.; Fujimaki, T.; Murakami, A.; and 12 others
      Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma.
      Invest. Ophthal. Vis. Sci. 45 4359-4367 (2004)
    33. Galbraith, G. M. P.; Pandey, J. P.
      Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata.
      Hum. Genet. 96 433-436 (1995)
    34. Garcia-Ruiz, C.; Colell, A.; Mari, M.; Morales, A.; Calvo, M.; Enrich, C.; Fernandez-Checa, J. C.
      Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice.
      J. Clin. Invest. 111 197-208 (2003)
    35. Gorman, J. D.; Sack, K. E.; Davis, J. C., Jr.
      Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha.
      New Eng. J. Med. 346 1349-1356 (2002)
    36. Guo, R.; Yamashita, M.; Zhang, Q.; Zhou, Q.; Chen, D.; Reynolds, D. G.; Awad, H. A.; Yanoso, L.; Zhao, L.; Schwarz, E. M.; Zhang, Y. E.; Boyce, B. F.; Xing, L.
      Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins.
      J. Biol. Chem. 283 23084-23092 (2008)
    37. Hase, H.; Ando, T.; Eldeiry, L.; Brebene, A.; Peng, Y.; Liu, L.; Amano, H.; Davies, T. F.; Sun, L.; Zaidi, M.; Abe, E.
      TNF-alpha mediates the skeletal effects of thyroid-stimulating hormone.
      Proc. Nat. Acad. Sci. 103 12849-12854 (2006)
    38. Herrmann, S.-M.; Ricard, S.; Nicaud, V.; Mallet, C.; Arveiler, D.; Evans, A.; Ruidavets, J.-B.; Luc, G.; Bara, L.; Parra, H.-J.; Poirier, O.; Cambien, F.
      Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity.
      Europ. J. Clin. Invest. 28 59-66 (1998)
    39. Hill, A. V. S.
      The immunogenetics of resistance to malaria.
      Proc. Assoc. Am. Phys. 111 272-277 (1999)
    40. Huang, M. T.-H.; Mortensen, B. L.; Taxman, D. J.; Craven, R. R.; Taft-Benz, S.; Kijek, T. M.; Fuller, J. R.; Davis, B. K.; Allen, I. C.; Brickey, W. J.; Gris, D.; Wen, H.; Kawula, T. H.; Ting, J. P.-Y.
      Deletion of ripA alleviates suppression of the inflammasome and MAPK by Francisella tularensis.
      J. Immun. 185 5476-5485 (2010)
    41. Inoko, H.; Trowsdale, J.
      Linkage of TNF genes to the HLA-B locus.
      Nucleic Acids Res. 15 8957-8962 (1987)
    42. Kamata, H.; Honda, S.; Maeda, S.; Chang, L.; Hirata, H.; Karin, M.
      Reactive oxygen species promote TNF-alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases.
      Cell 120 649-661 (2005)
    43. Kawane, K.; Ohtani, M.; Miwa, K.; Kizawa, T.; Kanbara, Y.; Yoshioka, Y.; Yoshikawa, H.; Nagata, S.
      Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages.
      Nature 443 998-1002 (2007)
    44. Keane, J; Gershon, S; Wise, R. P.; Mirabile-Levens, E.; Kasznica, J.; Schwieterman, W. D.; Siegel, J. N; Braun, M. M.
      Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
      N. Eng. J. Med. 345 1098-1104 (2001)
    45. Kim, J.-Y.; Moon, S.-M.; Ryu, H.-J.; Kim, J.-J.; Kim, H.-T.; Park, C.; Kimm, K.; Oh, B.; Lee, J.-K.
      Identification of regulatory polymorphisms in the TNF-TNF receptor superfamily.
      Immunogenetics 57 297-303 (2005)
    46. Kim, Y. J.; Lee, H.-S.; Yoon, J.-H.; Kim, C. Y.; Park, M. H.; Kim, L. H.; Park, B. L.; Shin, H. D.
      Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection.
      Hum. Molec. Genet. 12 2541-2546 (2003)
    47. Knight, J. C.; Udalova, I.; Hill, A. V. S.; Greenwood, B. M.; Peshu, N.; Marsh, K.; Kwiatkowski, D.
      A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria.
      Nature Genet. 22 145-150 (1999)
    48. Koss, K.; Satsangi, J.; Fanning, G. C.; Welsh, K. I.; Jewell, D. P.
      Cytokine (TNF-alpha, LT-alpha, and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies.
      Genes Immun. 1 185-190 (2000)
    49. Krikovszky, D.; Vasarhelyi, B.; Toth-Heyn, P.; Korner, A.; Tulassay, T.; Madacsy, L.
      Association between G(-308)A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents.
      Clin. Genet. 62 474-477 (2002)
    50. Laws, S. M.; Perneczky, R.; Wagenpfeil, S.; Muller, U.; Forstl, H.; Martins, R. N.; Kurz, A.; Riemenschneider, M.
      TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels.
      Hum. Mutat. 26 29-35 (2005)
    51. Lee, Y. H.; Harley, J. B.; Nath, S. K.
      Meta-analysis of TNF-alpha promoter -308A/G polymorphism and SLE susceptibility.
      Europ. J. Hum. Genet. 14 364-371 (2006)
    52. Leonardi, C. L.; Powers, J. L.; Matheson, R. T.; Goffe, B. S.; Zitnik, R.; Wang, A.; Gottlieb, A. B.
      Etanercept as monotherapy in patients with psoriasis.
      New Eng. J. Med. 349 2014-2022 (2003)
    53. Li, H.; Groop, L.; Nilsson, A.; Weng, J.; Tuomi, T.
      A combination of human leukocyte antigen DQB1*02 and the tumor necrosis factor alpha promoter G308A polymorphism predisposes to an insulin-deficient phenotype in patients with type 2 diabetes.
      J. Clin. Endocr. Metab. 88 2767-2774 (2003)
    54. Li, X.; Magenheimer, B. S.; Xia, S.; Johnson, T.; Wallace, D. P.; Calvet, J. P.; Li, R.
      A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease.
      Nature Med. 14 863-868 (2008)
    55. Lieu, Z. Z.; Lock, J. G.; Hammond, L. A.; La Gruta, N. L.; Stow, J. L.; Gleeson, P. A.
      A trans-Golgi network golgin is required for the regulated secretion of TNF in activated macrophages in vivo.
      Proc. Nat. Acad. Sci. 105 3351-3356 (2008)
    56. Ma, J. J.; Nishimura, M.; Mine, H.; Kuroki, S.; Nukina, M.; Ohta, M.; Saji, H.; Obayashi, H.; Kawakami, H.; Saida, T.; Uchiyama, T.
      Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome.
      Ann. Neurol. 44 815-818 (1998)
    57. Marino, M. W.; Dunn, A.; Grail, D.; Inglese, M.; Noguchi, Y.; Richards, E.; Jungbluth, A.; Wada, H.; Moore, M.; Williamson, B.; Basu, S.; Old, L. J.
      Characterization of tumor necrosis factor-deficient mice.
      Proc. Nat. Acad. Sci. 94 8093-8098 (1997)
    58. McCusker, S. M.; Curran, M. D.; Dynan, K. B.; McCullagh, C. D.; Urquhart, D. D.; Middleton, D.; Patterson, C. C.; McIlroy, S. P.; Passmore, A. P.
      Association between polymorphism in regulatory region of gene encoding tumour necrosis factor-alpha and risk of Alzheimer's disease and vascular dementia: a case-control study.
      Lancet 357 436-439 (2001)
    59. McGuire, W.; Hill, A. V. S.; Allsopp, C. E. M.; Greenwood, B. M.; Kwiatkowski, D.
      Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.
      Nature 371 508-511 (1994)
    60. Mira, J.-P.; Cariou, A.; Grall, F.; Delclaux, C.; Losser, M.-R.; Heshmati, F.; Cheval, C.; Monchi, M.; Teboul, J.-L.; Riche, F.; Leleu, G.; Arbibe, L.; Mignon, A.; Delpech, M.; Dhainaut, J.-F.
      Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study.
      JAMA 282 561-568 (1999)
    61. Moffatt, M. F.; Cookson, W. O. C. M.
      Tumour necrosis factor haplotypes and asthma.
      Hum. Molec. Genet. 6 551-554 (1997)
    62. Moraes, M. O.; Duppre, N. C.; Suffys, P. N.; Santos, A. R.; Almeida, A. S.; Nery, J. A. C.; Sampaio, E. P.; Sarno, E. N.
      Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients.
      Immunogenetics 53 45-47 (2001)
    63. Mulcahy, B.; Waldron-Lynch, F.; McDermott, M. F.; Adams, C.; Amos, C. I.; Zhu, D. K.; Ward, R. H.; Clegg, D. O.; Shanahan, F.; Molloy, M. G.; O'Gara, F.
      Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis.
      Am. J. Hum. Genet. 59 676-683 (1996)
    64. Muller, U.; Jongeneel, C. V.; Nedospasov, S. A.; Lindahl, K. F.; Steinmetz, M.
      Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex.
      Nature 325 265-267 (1987)
    65. Murray, R. Z.; Kay, J. G.; Sangermani, D. G.; Stow, J. L.
      A role for the phagosome in cytokine secretion.
      Science 310 1492-1495 (2005)
    66. Nadel, S.; Newport, M. J.; Booy, R.; Levin, M.
      Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease.
      J. Infect. Dis. 174 878-880 (1996)
    67. Nadkarni, S.; Mauri, C.; Ehrenstein, M. R.
      Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta.
      J. Exp. Med. 204 33-39 (2007)
    68. Nedospasov, S. A.; Hirt, B.; Shakhov, A. N.; Dobrynin, V. N.; Kawashima, E.; Accolla, R. S.; Jongeneel, C. V.
      The genes for tumor necrosis factor (TNR-alpha) and lymphotoxin (TNR-beta) are tandemly arranged on chromosome 17 of the mouse.
      Nucleic Acids Res. 14 7713-7725 (1986)
    69. Nedwin, G. E.; Naylor, S. L.; Sakaguchi, A. Y.; Smith, D.; Jarrett-Nedwin, J.; Pennica, D.; Goeddel, D. V.; Gray, P. W.
      Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization.
      Nucleic Acids Res. 13 6361-6373 (1985)
    70. Norman, R. A.; Bogardus, C.; Ravussin, E.
      Linkage between obesity and a marker near the tumor necrosis factor-alpha locus in Pima Indians.
      J. Clin. Invest. 96 158-162 (1995)
    71. Obayashi, H.; Hasegawa, G.; Fukui, M.; Kamiuchi, K.; Kitamura, A.; Ogata, M.; Kanaitsuka, T.; Shigeta, H.; Kitagawa, Y.; Nakano, K.; Nishimura, M.; Ohta, M.; Nakamura, N.
      Tumor necrosis factor microsatellite polymorphism influences the development of insulin dependency in adult-onset diabetes patients with the DRB1*1502-DQB1*0601 allele and anti-glutamic acid decarboxylase antibodies.
      J. Clin. Endocr. Metab. 85 3348-3351 (2000)
    72. Obeid, L. M.; Linardic, C. M.; Karolak, L. A.; Hannun, Y. A.
      Programmed cell death induced by ceramide.
      Science 259 1769-1771 (1993)
    73. Old, L. J.
      Tumor necrosis factor (TNF).
      Science 230 630-632 (1985)
    74. Ota, N.; Hunt, S. C.; Nakajima, T.; Suzuki, T.; Hosoi, T.; Orimo, H.; Shirai, Y.; Emi, M.
      Linkage of human tumor necrosis factor-alpha to human osteoporosis by sib-pair analysis.
      Genes Immunity 1 260-264 (2000)
    75. Pennica, D.; Nedwin, G. E.; Hayflick, J. S.; Seeburg, P. H.; Derynck, R.; Palladino, M. A.; Kohr, W. J.; Aggarwal, B. B.; Goeddel, D. V.
      Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
      Nature 312 724-729 (1984)
    76. Quasney, M. W.; Zhang, Q.; Sargent, S.; Mynatt, M.; Glass, J.; McArthur, J.
      Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia.
      Ann. Neurol. 50 157-162 (2001)
    77. Ragoussis, J.; Bloemer, K.; Weiss, E. H.; Ziegler, A.
      Localization of the genes for tumor necrosis factor and lymphotoxin between the HLA class I and III regions by field inversion gel electrophoresis.
      Immunogenetics 27 66-69 (1988)
    78. Rainero, I.; Grimaldi, L. M. E.; Salani, G.; Valfre, W.; Rivoiro, C.; Savi, L.; Pinessi, L.
      Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine.
      Neurology 62 141-143 (2004)
    79. Ramos, E. M.; Lin, M.-T.; Larson, E. B.; Maezawa, I.; Tseng, L.-H.; Edwards, K. L.; Schellenberg, G. D.; Hansen, J. A.; Kukull, W. A.; Jin, L.-W.
      Tumor necrosis factor-alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease.
      Arch. Neurol. 63 1165-1169 (2006)
    80. Rasmussen, S. K.; Urhammer, S. A.; Jensen, J. N.; Hansen, T.; Borch-Johnsen, K.; Pedersen, O.
      The -238 and -308 G6A polymorphisms of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians.
      J. Clin. Endocr. Metab. 85 1731-1734 (2000)
    81. Roach, D. R.; Bean, A. G.; Demangel, C.; France, M. P.; Briscoe, H.; Britton, W.J.
      TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection.
      J. Immun. 168 4620-4627 (2002)
    82. Rosmond, R.; Chagnon, M.; Bouchard, C.; Bjorntorp, P.
      G-308A polymorphism of the tumor necrosis factor alpha gene promoter and salivary cortisol secretion.
      J. Clin. Endocr. Metab. 86 2178-2180 (2001)
    83. Roy, S.; McGuire, W.; Mascie-Taylor, C. G.; Saha, B.; Hazra, S. K.; Hill, A. V.; Kwiatkowski, D.
      Tumor necrosis factor promoter polymorphism and susceptibility to lepromatous leprosy.
      J. Infect. Dis. 176 530-532 (1997)
    84. Ruuls, S. R.; Sedgwick, J. D.
      Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models.
      Am. J. Hum. Genet. 65 294-301 (1999)
    85. Shbaklo, H.; Azar, S. T.; Terwedow, H.; Halaby, G.; Naja, R. P.; Zalloua, P. A.
      No association between the -1031 polymorphism in the TNF-alpha promoter region and type 1 diabetes.
      Hum. Immun. 64 633-638 (2003)
    86. Shin, H. D.; Park, B. L.; Kim, L. H.; Jung, J. H.; Wang, H. J.; Kim, Y. J.; Park, H.-S.; Hong, S.-J.; Choi, B. W.; Kim, D.-J.; Park, C.-S.
      Association of tumor necrosis factor polymorphisms with asthma and serum total IgE.
      Hum. Molec. Genet. 13 397-403 (2004)
    87. Shirai, T.; Yamaguchi, H.; Ito, H.; Todd, C. W.; Wallace, R. B.
      Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor.
      Nature 313 803-806 (1985)
    88. Skoog, T.; van't Hooft, F. M.; Kallin, B.; Jovinge, S.; Boquist, S.; Nilsson, J.; Eriksson, P.; Hamsten, A.
      A common functional polymorphism (C-A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha.
      Hum. Molec. Genet. 8 1443-1449 (1999)
    89. Soller, J. T.; Murua-Escobar, H.; Willenbrock, S.; Janssen, M.; Eberle, N.; Bullerdiek, J.; Nolte, I.
      Comparison of the human and canine cytokines IL-1(alpha/beta) and TNF-alpha to orthologous other mammalians.
      J. Hered. 98 485-490 (2007)
    90. Spielman, R. S.; McGinnis, R. E.; Ewens, W. J.
      Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM).
      Am. J. Hum. Genet. 52 506-516 (1993)
    91. Spies, T.; Morton, C. C.; Nedospasov, S. A.; Fiers, W.; Pious, D.; Strominger, J. L.
      Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex.
      Proc. Nat. Acad. Sci. 83 8699-8702 (1986)
    92. Steed, P. M.; Tansey, M. G.; Zalevsky, J.; Zhukovsky, E. A.; Desjarlais, J. R.; Szymkowski, D. E.; Abbott, C.; Carmichael, D.; Chan, C.; Cherry, L.; Cheung, P.; Chirino, A. J.; and 22 others
      Inactivation of TNF signaling by rationally designed dominant-negative TNF variants.
      Science 301 1895-1898 (2003)
    93. Stein, C. M.; Nshuti, L.; Chiunda, A. B.; Boom, W. H.; Elston, R. C.; Mugerwa, R. D.; Iyengar, S. K.; Whalen, C. C.
      Evidence for a major gene influence on tumor necrosis factor-alpha expression in tuberculosis: path and segregation analysis.
      Hum. Hered. 60 109-118 (2005)
    94. Stellwagen, D.; Malenka, R. C.
      Synaptic scaling mediated by glial TNF-alpha.
      Nature 440 1054-1059 (2006)
    95. Szalai, C.; Fust, G.; Duba, J.; Kramer, J.; Romics, L.; Prohaszka, Z.; Csaszar, A.
      Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease.
      J. Med. Genet. 39 46-51 (2002)
    96. Takahashi, J. L.; Giuliani, F.; Power, C.; Imai, Y.; Yong, V. W.
      Interleukin-1-beta promotes oligodendrocyte death through glutamate excitotoxicity.
      Ann. Neurol. 53 588-595 (2003)
    97. Tay, S. Hughey, J. J.; Lee, T. K.; Lipniacki, T.; Quake, S. R.; Covert, M. W.
      Single-cell NF-kappa-B dynamics reveal digital activation and analogue information processing.
      Nature 466 267-271 (2010)
    98. Uysal, K. T.; Wiesbrock, S. M.; Marino, M. W.; Hotamisligil, G. S.
      Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function.
      Nature 389 610-614 (1997)
    99. van Heel, D. A.; Udalova, I. A.; De Silva, A. P.; McGovern, D. P.; Kinouchi, Y.; Hull, J.; Lench, N. J.; Cardon, L. R.; Carey, A. H.; Jewell, D. P.; Kwiatkowski, D.
      Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-kappa-B transcription factors.
      Hum. Molec. Genet. 11 1281-1289 (2002)
    100. van Hensbroek, M. B.; Palmer, A.; Onyiorah, E.; Schneider, G.; Jaffar, S.; Dolan, G.; Memming, H.; Frenkel, J.; Enwere, G.; Bennett, S.; Kwiatkowski, D.; Greenwood, B.
      The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria.
      J. Infect. Dis. 174 1091-1097 (1996)
    101. Van Ostade, X.; Vandenabeele, P.; Everaerdt, B.; Loetscher, H.; Gentz, R.; Brockhaus, M.; Lesslauer, W.; Tavernier, J.; Brouckaert, P.; Fiers, W.
      Human TNF mutants with selective activity on the p55 receptor.
      Nature 361 266-269 (1993)
    102. Vielhauer, V.; Stavrakis, G.; Mayadas, T. N.
      Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis.
      J. Clin. Invest. 115 1199-1209 (2005)
    103. Wang, A. M.; Creasey, A. A.; Ladner, M. B.; Lin, L. S.; Strickler, J.; Van Arsdell, J. N.; Yamamoto, R.; Mark, D. F.
      Molecular cloning of the complementary DNA for human tumor necrosis factor.
      Science 228 149-154 (1985)
    104. Wilson, A. G.; di Giovine, F. S.; Blakemore, A. I. F.; Duff, G. W.
      Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product.
      Hum. Molec. Genet. 1 353 (1992)
    105. Wilson, A. G.; Symons, J. A.; McDowell, T. L.; et al
      Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.
      Proc. Nat. Acad. Sci. 94 3195-3199 (1997)
    106. Winchester, E. C.; Millwood, I. Y.; Rand, L.; Penny, M. A.; Kessling, A. M.
      Association of the TNF-alpha-308 (G-A) polymorphism with self-reported history of childhood asthma.
      Hum. Genet. 107 591-596 (2000)
    107. Witte, J. S.; Palmer, L. J.; O'Connor, R. D.; Hopkins, P. J.; Hall, J. M.
      Relation between tumour necrosis factor polymorphism TNF-alpha-308 and risk of asthma.
      Europ. J. Hum. Genet. 10 82-85 (2002)
    108. Zinman, B.; Hanley, A. J. G.; Harris, S. B.; Kwan, J.; Fantus, I. G.
      Circulating tumor necrosis factor-alpha concentrations in a Native Canadian population with high rates of type 2 diabetes mellitus.
      J. Clin. Endocr. Metab. 84 272-278 (1999)
    OMIM and Online Mendelian Inheritance in Man are registered trademarks of the Johns Hopkins University. Copyright 1966-2011 Johns Hopkins University.



    HPRD (Human Protein Reference Database)

    Proteins Linked to TNF Gene: 12